EN DE
Watch Reflect Scientific Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Reflect Scientific Inc (RSCF) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Reflect Scientific Inc stock $0.05, price $0.06, that is 22.7% below the price, quality 61 out of 100. Rating: overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

RS Reflect Scientific Inc logo Thin data Nov 4, 2026

Reflect Scientific Inc

RSCF · US
Solid, but expensive

Our calculation puts a fair price 23% below what the stock costs today.

Quality 61/100
Low debt
Mixed Growth (revenue 5y +3.1 %/yr in USD)
Loss over the last twelve months · -1.7% net margin (TTM) · fiscal year 2025 13.0%
Mixed vs. peers (5/11)
Fair value $0.0464 · Overvalued
Negative free cash flow
Narrow moat 36/100 · thin data
Thin data
⚠ Thinly traded
Watch Reflect Scientific Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.4300 $0.0350 Fair Value $0.0464 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $0.0350 – $0.4300 · fair‑value band $0.0410 – $0.0518 · the $0.0600 price screens above the $0.0464 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 4, 2026.

Follow Reflect Scientific in your weekly email

Every Wednesday you see whether Reflect Scientific is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Reflect Scientific, Inc., through its subsidiaries, engages in the design, development, and sale of scientific equipment for the life science and manufacturing industries worldwide.

Show moreShow less

The company offers Cryometrix ultra-low temperature and blast freezers, which are used to store various products, including blood and cancer vaccines.

It also provides laboratory consumables and disposables, such as filtration and purification products, customized sample handling vials, electronic wiring assemblies, high temperature silicone, and graphite and vespel/graphite sealing components for use by original equipment manufacturers in the field of gas/liquid chromatography in the chemical analysis industries.

In addition, the company offers solvent chillers and refrigerated transportation products; and UV detectors and vial products.

It serves hospitals, diagnostic laboratories, pharmaceutical and biotech companies, universities, governments, and private sector research facilities, as well as cold chain management, chemical, and industrial companies. The company was founded in 1999 and is based in Orem, Utah.

Stock analysis

Reflect Scientific Inc (RSCF) currently trades at $0.0600, while our model-based Fair Value estimate is $0.0464, 23% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $0.0500 per share, and 1 of the 12 models we run sit above the $0.0600 price.

Bear case: the Asset-Based group reads lowest at $0.0200, and 11 of the 12 models stay below the price. Data coverage for this calculation is low.

Scenario range: $0.0410 (bear) to $0.0518 (bull), the price of $0.0600 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.

Reflect Scientific Inc reported revenue of $1.6M in FY2025 versus $2.8M in FY2021, a compound −13.0%/yr. Reported net income was $210K in FY2025, compounding −31.3%/yr from FY2021.

Key figures

Market cap $5.1M Micro · P/S ratio 2.99 · EPS (TTM) $−0.0100 · Net margin 13.0% · Return on equity −1.4% · Return on assets (EBIT) 6.2% (5-year average) · Operating margin 19.3% · Revenue (TTM) $1.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 36 out of 100 (low confidence).

What moves the price

The share trades about 7% below its 52-week high and 71% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −23%, RSCF screens cheaper than that median.

Fair Value models

Bear $0.0410 Fair Value $0.0464 Bull $0.0518
Price $0.0600 · Downside -22.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV $0.0300 $0.0400 $0.0400 74
ROIC Compounder $0.0300 $0.0400 $0.0400 72
Residual Income $0.0200 $0.0200 $0.0300 71
All 12 models by family
Earnings-Based
Graham-Dodd $0.0200 $0.0300 $0.0400 66
EPV $0.0300 $0.0400 $0.0400 74
Multiples
P/E Multiple $0.0400 $0.0500 $0.0700 62
P/S Multiple $0.0300 $0.0400 $0.0500 58
P/B Multiple $0.0900 $0.1200 $0.1500 55
EV/EBIT $0.0500 $0.0500 $0.0600 66
EV/EBITDA $0.0500 $0.0600 $0.0700 67
EV/Revenue $0.0400 $0.0500 $0.0500 54
Asset-Based
NCAV (Graham) $0.0200 $0.0200 $0.0300 55
Economic Profit
Residual Income $0.0200 $0.0200 $0.0300 71
ROIC Compounder $0.0300 $0.0400 $0.0400 72
Growth Earnings
Growth-Adj P/E $0.0300 $0.0400 $0.0500 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 61/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 45
How much profit the company makes from its sales and capital
Quality Growth 45
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 92
Does it invest with discipline instead of growing at any price?
Low Volatility 3
How calm the share price moves, does not count
Price momentum 78
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2025: revenue and profit before it include the divested business. Growth is measured afresh from 2025.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.1%
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−25.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−25.0%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−23.7% vs −16.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23% → 10%
2025 sits 62% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 3.7%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

RSCF screens overvalued: fair value 23% below the price. Compare with Intuitive Surgical, Inc →

Compare Reflect Scientific Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 61 · Above median
Fair Value upside −22.7% · Below median
Profitability
Return on assets 7.5% · Above median
Net margin (12 months) −1.7% · Bottom 25%
Operating margin (12 months) 19.3% · Above median
Growth and dividend
Revenue growth (quarter YoY) −2.3% · Bottom 25%
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 2.26× · Pricier than median
P/S (12 months) 2.99× · Pricier than median
EV/EBITDA 4.1× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)3 · sector 25
FUTURE (revenue growth)0 · sector 40
PAST (return on equity)0 · sector 30
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)0 · sector 32

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.38 $131.27 +45% vs RSCF
EssilorLuxottica Société anonyme EL €193.80 €196.22 +1% vs RSCF
Intuitive Surgical, Inc ISRG $452.80 $353.90 −22% vs RSCF
Medline Inc MDLN $39.64 $28.59 −28% vs RSCF
Alcon Inc ALC CHF 61.30 CHF 34.06 −44% vs RSCF
Becton, Dickinson and Company BDX $211.88 $97.80 −54% vs RSCF
Straumann Holding STMN CHF 104.50 CHF 45.50 −56% vs RSCF
West Pharmaceutical Services, Inc WST $399.81 $139.22 −65% vs RSCF
Sartorius Stedim Biotech S.A DIM €225.80 €54.82 −76% vs RSCF
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs RSCF

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Reflect Scientific Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Reflect Scientific Inc Fair Value". https://www.fairvalue-calculator.com/stock/RSCF

Frequently asked questions

Is Reflect Scientific Inc (RSCF) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $0.0464 versus a price of $0.0600, about 23% lower (overvalued).
What is the fair value of RSCF?
Our model-based fair value for Reflect Scientific Inc is $0.0464 (as of Nov 4, 2026), built from audited fundamentals. The current price: $0.0600.
What is the quality score of RSCF?
Reflect Scientific Inc has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Reflect Scientific Inc (RSCF)?
Our model-based price target is the fair value of $0.0464 (as of Nov 4, 2026) from 12 valuation models. Cautious scenario $0.0410, optimistic scenario $0.0518. It is a calculation from audited fundamentals, not an analyst target.
What is the Reflect Scientific Inc stock forecast for 2026?
Our models put fair value at $0.0464, about 23% lower versus a price of $0.0600 (overvalued). Cautious scenario $0.0410, optimistic scenario $0.0518. The calculation is refreshed regularly with new filings.
What is the revenue of Reflect Scientific Inc (RSCF)?
Reflect Scientific Inc reported trailing-twelve-month revenue of about $1.7M (latest available figure, as of Nov 4, 2026).
What is the intrinsic value of Reflect Scientific Inc (RSCF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Reflect Scientific Inc it is $0.0464 per share (as of Nov 4, 2026), against a price of $0.0600. It is the blended result of 12 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Reflect Scientific Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, RSCF trades above its calculated fair value: price $0.0600, fair value $0.0464, a gap of about −23% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RSCF?
No. The price is what the market pays today ($0.0600); the fair value is what the company's own numbers justify ($0.0464). For Reflect Scientific Inc the two are $0.0136 per share apart. That gap is exactly why we show both numbers side by side.
How much is Reflect Scientific Inc worth?
The market values Reflect Scientific Inc at about $5.1M (market capitalisation, as of Nov 4, 2026). Per share that is $0.0600; our models calculate a fair value of $0.0464 per share.
What do the bullish and bearish scenarios say about RSCF?
Our models span a range for Reflect Scientific Inc: cautious scenario $0.0410, base $0.0464, optimistic $0.0518 per share (as of Nov 4, 2026, price $0.0600). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Reflect Scientific Inc (RSCF)?
Balance-sheet figures for Reflect Scientific Inc (as of Nov 4, 2026): return on equity −1.4%, debt of 0.05 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is RSCF from its 52-week high?
Reflect Scientific Inc trades at $0.0600, about 7% below its 52-week high of $0.0645 and 71% above the low of $0.0350 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0464 is for.
Which stocks are comparable to Reflect Scientific Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Reflect Scientific Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $0.0600, calculated fair value $0.0464 (−23%), Quality Score 61/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RSCF calculated?
We run Reflect Scientific Inc through 12 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $0.0464 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Reflect Scientific Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Reflect Scientific Inc (RSCF)?
The closing price on Nov 6, 2026 was $0.0600. Our model-based fair value is $0.0464, about 23% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Reflect Scientific Inc right now?
The price sits above even our optimistic bull case ($0.0518). The favourable scenario is already priced in. Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Reflect Scientific Inc

How large is the market capitalisation of Reflect Scientific Inc (RSCF)?
The market capitalisation of Reflect Scientific Inc is $5.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Reflect Scientific Inc (RSCF)?
The price-to-sales ratio of Reflect Scientific Inc is 2.99 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Reflect Scientific Inc (RSCF)?
Earnings per share at Reflect Scientific Inc are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Reflect Scientific Inc (RSCF)?
The net margin of Reflect Scientific Inc is 13.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Reflect Scientific Inc (RSCF)?
The return on equity (ROE) of Reflect Scientific Inc is −1.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Reflect Scientific Inc (RSCF)?
On an EBIT basis the return on assets of Reflect Scientific Inc is 6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Reflect Scientific Inc (RSCF)?
The operating margin of Reflect Scientific Inc is 19.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Reflect Scientific Inc (RSCF)?
Revenue at Reflect Scientific Inc is growing −2.3% versus a year earlier (3y avg −12.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Reflect Scientific Inc (RSCF)?
Earnings per share at Reflect Scientific Inc are growing +27.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Reflect Scientific Inc (RSCF) generate?
The free cash flow of Reflect Scientific Inc is −$104K (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Reflect Scientific Inc (RSCF) hold?
Reflect Scientific Inc holds more cash than debt, $1.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Reflect Scientific Inc in the live analysis

One click puts Reflect Scientific Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.